$8.85 Million is the total value of Yu Fan's 4 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ABGI | ABG ACQUISITION CORP I | $4,913,000 | -0.9% | 501,300 | 0.0% | 55.52% | +329.0% | |
| AVIR | Sell | ATEA PHARMACEUTICALS INC | $3,090,000 | -83.3% | 143,867 | -52.0% | 34.92% | -27.8% |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $780,000 | -12.1% | 112,044 | 0.0% | 8.82% | +280.8% | |
| DIFFUSION PHARMACEUTICALS IN | $66,000 | -19.5% | 89,848 | 0.0% | 0.75% | +248.6% | ||
| LUNG | Exit | PULMONX CORP | $0 | – | -303,030 | -100.0% | -36.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-09-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CASTLE BIOSCIENCES INC | 12 | Q3 2023 | 24.7% |
| ABG ACQUISITION CORP I | 8 | Q4 2022 | 83.9% |
| SONENDO INC | 8 | Q3 2023 | 60.4% |
| PRENETICS GLOBAL LTD | 6 | Q3 2023 | 1.9% |
| DIFFUSION PHARMACEUTICALS IN | 6 | Q1 2022 | 0.8% |
| CASTLE BIOSCIENCES INC | 5 | Q2 2023 | 25.8% |
| APEXIGEN INC | 4 | Q2 2023 | 14.8% |
| ATEA PHARMACEUTICALS INC | 3 | Q2 2021 | 61.3% |
| PULMONX CORP | 2 | Q1 2021 | 36.2% |
| SAGIMET BIOSCIENCES INC | 1 | Q3 2023 | 35.7% |
View Yu Fan's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Pulmonx Corp | February 11, 2022 | 31,903 | 0.1% |
View Yu Fan's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 4 | 2023-03-03 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Yu Fan's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.